Sequence of treatment is important in the modification of camptothecin induced cell killing by hyperthermia

International Journal of Hyperthermia

Volumn 12, Issue 5, 1996, Pages 663-678

  Ng, C E ^a   Bussey, A M ^a   Raaphorst, G P ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Camptothecin; Hyperthermia; Topoisomerase activity

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE;

ARTICLE; CELL KILLING; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; MELANOMA;

EID: 0030002719     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.3109/02656739609027674     Document Type: Article

References (41)

1. BICHAY, T. J., FEELEY, M. M., and RAAPHORST, G. P., 1992, A comparison of heat sensitivity, radiosensitivity and PLDR in four human melanoma cell lines. Melanoma Research, 2, 63-69.
2. CHOW, K. C., and ROSS, W. E., 1987, Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Molecular and Cellular Biology, 7, 3119-3123.
3. DEL BINO, G., SKIERSKI J. S., and DARZYNKIEWICZ, Z., 1990 Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Research, 50, 5746-5750.
4. DEL BINO, G., LASSOTA, P., and DARZYNKIEWICZ, Z., 1991, The S-phase cytotoxicity of camptothecin. Experimental Cell Research, 193, 27-35.
5. DEWHIRST, M., 1994, Future directions in hyperthermic biology. International Journal of Hyperthermia, 10, 339-345.
6. DYNLACHT, J. R., WONG, R. S. L., ALBRIGHT, N., and DEWEY, W. C., 1994, Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes. Cancer Research, 54, 4129-4137.
7. GIOVANELLA, B. C., STEHLIN, J. S., WALL, M. E., WANI, M. C., NICHOLAS, A. W., LIU, L. F., SILBER, R., and POTMESIL, M., 1989, DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048.
8. GOSWAMI, P. C., HILL, M., HIGASHIKUBO, R., WRIGHT, W. D., and ROTI ROTI, J. L., 1992, The suppression of the synthesis of a nuclear protein in cells blocked in G2 phase: identification of NP-170 as topoisomerase II. Research Research, 132, 162-167.
9. HAHN, G. M., 1982, Hyperthermia and Cancer, (New York: Plenum Press), pp. 74-85
10. HALL, E. J., 1994. Radiobiology for the Radiologist, (Philadelphia: J. P. Lippincott) edn 4.
11. HECK, M. M. S., HITTELMAN, W. N., and EARNSHAW, W. C., 1988, Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. PNAS USA, 85, 1086-1090.
12. HERMAN, T. S., and TEICHER, B. A., 1994, Summary of studies adding systemic chemotherapy to local hyperthermia and radiation. International Journal of Hyperthermia, 10, 443-449.
13. HOCHHAUSER, D., and HARRIS, A. L., 1993, The laboratory-clinic interface. The role of topoisomerase II α and β in drug resistance. Cancer Treatment Reviews, 19, 181-194.
14. HOLDEN, J. A., ROLFSON, D. H , and WILTWER, C. T., 1990, Human DNA topoisomerase II: Evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry, 29, 2127-2134.
15. HSIANG, Y. H., LIHOU, M. G., and LIU, L. F., 1989, Arrest of replication forks by drug-stabilized topoisomerase I-DNA Cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Research, 49, 5077-5082.
16. HUSAIN, I., MOHLER, J. L., SEIGLER, H. F., and BESTERMAN, J. M., 1994, Elevation of topoisomerase I-messenger RNA, protein and catalytic activity in human tumors: Demonstration of tumor type specificity and implications for cancer chemotherapy. Cancer Research, 54, 539-546.
17. KAMPINGA, H. H., 1995, Hyperthermia, thermotolerance and topoisomerase II inhibitors. British Journal of Cancer, 72, 333-338.
18. KONDO, T., UEDA, K., and KANO, E., 1995, Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells. Anticancer Research, 15, 83-86.
19. LEPOCK, J., 1982, Involvement of membranes in cellular responses to hyperthermia. Radiation Research, 92, 433-438.
20. LIU, L. F., 1989, Topoisomerases poisons as antitumor drugs. Annals of Review in Biochemistry, 58, 351-375.
21. MACKEY, M. A., and DEWEY, W. C., 1989, Cell cycle progression during chronic hyperthermia in S phase CHO cells. International Journal of Hyperthermia, 5, 405-413.
22. MATSUO, K., KOHNO, K., SATAO, S., UCHIUMI, K. T., TANIMURA, H., YAMADA, Y., and KUWANO, M., 1993, Enhanced expression of DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Research, 53, 1085-1090.
23. NG, C. E., BUSSEY, A. M., MACDONALD, H. A., HELLER, D. P., WILKINS, D. E., and RAAPHORST, G. P., 1995, Cross sensitivity to x-radiation and type I and II DNA topoisomerase inhibitors in a range of human and rodent cell lines. International Journal of Oncology, 7, 1179-1184.
24. NG, C. E., BUSSEY, A. M. and RAAPHORST, G. P., 1996, Reduction of etoposide induced cell killing by hyperthermia can occur without changes in etoposide transport or DNA topoisomerase II activity. International Journal of Hyperthermia, (in press).
25. O'CONNOR, P. M., NIEVES-NEIRA, W., KERRIGAN, D., POMMIER, Y., BERTRAND, R., GOLMAN, J., and KAHN, K. W., 1991, S phase population analysis does not correlate with cytotoxicity of camptothecin and 10,11-methylene-dioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Communications, 3, 233-240.
26. POMMIER, Y., LETEURTRE, F., FESEN, M. R., and FUJIMORI, A., 1994, Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investigations, 12, 530-542.
27. POTMESIL, M., HSIANG, Y., LIU, L. F., BANK, B., GROSSBERG, H., KIRSCHENBAUM, S., FORLENZAR, T. J., PENZINER, A., KANGANIS, D., KNOWLES, D., TROGANOS, F., and SILBER, R., 1988, Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Research, 48, 3537-3543.
28. POTMESIL, M. and PINEDO, H. E., 1995, Camptothecins: New anticancer agents, (Boca Raton: CRC Press), Chapter 1.
29. PROSPERI, E., SALA, E., NEGRI, C., OLIANI, C., SUPINO, R., GIULIA, B. C., RICOTTI, A., and BOTTIROLI, G., 1992, Topoisomerase IIα and β in human tumor cells grown in vitro and in vivo. Anticancer Research, 12, 2093-2100.
30. READ, R. A., Fox, M. H., and BEDFORD, J. S., 1984, The cell cycle dependence of thermotolerance II. CHO cells heated at 45·0°C. Radiation Research, 98, 491-505.
31. RYAN, A. J., SQUIRES, S., STRUTT, H. L., and JOHNSON, R. T., 1991, Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Research, 9, 3295-3300.
32. SAPARETO, S. A., HOPWOOD, L. E., DEWEY, W. C., FAJU, M. R., and GRAY, J. W., 1978, Effect of hyperthermia on survival and progression of CHO cells. Cancer Research, 38, 393-400.
33. SLICHENMYER, W. J., ROWINSKY, E. K., DONEHOWER, R. C., and KAUFMAN, S. H., 1993, The current status of camptothecin analogues as antitumor agents. Journal of the National Cancer Institute, 85, 271-291.
34. SULLIVAN, D. M., GLISSON, B. S., HODGES, P. K., SMALLWOOD-KENTZO, S., and ROSS, W. E., 1986, Proliferation dependence of topoisomerase II mediated drug action. Biochemistry, 25, 2248-2256.
35. TAKANO, H., KOHNO, K., ONO, M., UCHIDA, Y., and KUWANO, M., 1991, Increased phophorylation of DNA topoisomerase II in etoposide resistance mutants of human cancer KB cells. Cancer Research, 51, 3951-3957.
36. TEICHER, B. A., HOLDEN, S. A., KHANDAKAR, V., and HERMAN, T. S., 1993, Addition of a topoisomerase I inhibitor to trimodality [cisdiamminedichloroplatinum (II)/heat/ radiation] in a murine tumour. Journal of Cancer Research and Clinical Oncology, 119, 645-651.
37. TOFFOLI, G., BEVILACQUA, C., FRANCHECHIN, A., and BOIOCCHI, M., 1989, Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukemia cell lines. International Journal of Hyperthermia, 5, 163-172.
38. TRICOLI, J. V., SAHI, B. M., MCCORMICK, P. J., and JARLINSKI, S. J., 1985, DNA topoisomerase I and II activities during cell proliferation and the cell cycle in culture mouse embryo fibroblast (C3H 10T1/2) cells. Experimental Cell Research, 158, 1-14.
39. TSAO, Y., RUSSO, A., NYAMUSWA, G., SILBER, R., and LIU, L. F., 1993, Interaction between replication forks and topoisomerase I - DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Research, 53, 5908-5914.
40. WARTERS, R. L. and BARROWS, L. R., 1994, The heat sensitivity of HeLa S3 cell DNA topoisomerase II. Journal of Cellular Physiology, 159, 468-474.
41. WOESSNER, R. D., MATTERN, M. R., MIRABELLI, C. K., JOHNSON, R. K., and DRAKE, F. H., 1991, Proliferation and cell-cycle dependence differences in expressions of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth and Differentiation, 2, 209-214.